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FibroblastWe have demonstrated that scar formation after myocardial infarction (MI) is associated with an endogenous
pool of CD44posCD45neg multipotential mesenchymal stem cells (MSC). MSC differentiate into ﬁbroblasts secret-
ing collagen that forms a scar and mature into myoﬁbroblasts that express alpha smooth muscle actin (α-SMA)
that stabilizes the scar. In the aging mouse, cardiac repair after MI is associated with impaired differentiation of
MSC; MSC derived from the aged hearts form dysfunctional ﬁbroblasts that deposit less collagen in response to
transforming growth factor beta-1 (TGF-β1) and poorly mature into myoﬁbroblasts. We found in vitro that the
defect in myoﬁbroblast maturation can be remedied by AICAR, which activates non-canonical TGF-β signaling
through AMP-activated protein kinase (AMPK). In the present study, we injected aged mice with AICAR and
subjected them to 1 h occlusion of the left anterior descending artery (LAD) and then reperfusion for up to
30 days. AICAR-dependent AMPK signaling led to mobilization of an endogenous CD44posCD45neg MSC and its
differentiation towardsﬁbroblasts andmyoﬁbroblasts in the infarct. Thiswas accompanied by enhanced collagen
deposition and collagenﬁbermaturation in the scar. The AICAR-treated grouphas demonstrated reduced adverse
remodeling as indicated by improved apical end diastolic dimension but no changes in ejection fraction and car-
diac output were observed. We concluded that these data indicate the novel, previously not described role of
AMPK in the post-MI scar formation. Theseﬁndings can potentially lead to a new therapeutic strategy for preven-
tion of adverse remodeling in the aging heart.
© 2013 The authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The elderly population is increasing, in part due to improvements
in medical care. Because the number of older patients suffering from
cardiovascular disease has increased and because older patients often
survive MI but subsequently demonstrate adverse remodeling, the fre-
quency of congestive heart failure has strikingly risen [1].
Our studies in the aging mouse model demonstrate that cardiac re-
pair after experimental MI is impaired as early as ten months of age,
with progressive impairment extending through 24 months [2,3]. The
size of the induced MI is not larger; the major pathological feature is a
poorly organized scar with reduced ﬁbroblast and myoﬁbroblast con-
tent. In the aged heart participating myoﬁbroblasts/ﬁbroblasts deposit
substantially less collagen in the injured area when compared to the
young hearts [3], leading to adverse remodeling.
We have previously demonstrated that cardiac repair after MI is as-
sociated with an endogenous pool of CD44posCD45neg multipotentialepartment of Medicine, Division
0, Houston, Texas 77030, USA.
. Open access under CC BY license.MSC that rapidly proliferates within the infarct a few days after MI [4].
These cells differentiate into collagen secreting ﬁbroblasts that form a
scar and later mature into myoﬁbroblasts expressing α-SMA that con-
tract the scar and these processes are mediated by TGF-β1 signaling
[5,6]. Effective collagen deposition within a scar is a very speciﬁc and
targeted process that allows efﬁcient healing after MI [7]. Impairment
or delay of these reparative ﬁbrotic responses is associated with in-
creased dilative remodeling. By contrast, increased ﬁbrosis in a non-
reparative setting is found interstitially in the left ventricle in cardiac
hypertrophy and failure and is associated with cardiac dysfunction [8].
Recently we reported that ﬁbroblasts derived from the aged murine
heart are defective; they matured poorly into myoﬁbroblasts, displayed
reduced motility towards TGF-β1, and did not effectively increase
expression of collagen type I in response to TGF-β1, all as a result of
reduced expression of the TGF-β receptor I (TβRI) [9]. Interestingly,
in vitro, we were able to rescue the aged myoﬁbroblast maturation
through AICAR activation of AMPK and its downstream kinase
p38MAPK (that is, a non-canonical TGF-β signaling pathway) [9]. The
role of AMPK in ischemia has been extensively studied by many groups
[10–12]. It has been demonstrated that AMPK deletion has a detrimen-
tal effect on the ischemic heart [13]; AMPK in the ischemic heart main-
tains cardiomyocyte metabolism by promoting fatty acid oxidation
and glycolysis [11,14]. However AMPK serves also as a key mediator
in non-metabolic processes; AMPK (or its activator, AICAR) promotes
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MSC [17] and endothelial progenitors [18].
Based on our previous work showing impaired healing after MI in
older mice [2,3] and defects in MSC/ﬁbroblasts/myoﬁbroblasts derived
from the aged hearts, as well as in vitro rescue of the defective phenotype
via an AMPKdependent pathway [9], we hypothesized that in vivo activa-
tion of AMPK might mobilize ﬁbroblast precursors and enhance scar for-
mation in the aged injured heart. Because the attenuated healing capacity
afterMIwas observed inmiddle agedmice (as early as 14 months of age)
[2], we used 14 month old mice for the proof of concept. Mice were
injected with AICAR or saline for 7 days starting 2 days before ischemia
reperfusion injury (MI), and then animals were followed for up to
30 days. Our data indicate that AICAR-dependent AMPK signaling leads
to greater activation of endogenous CD44posCD45negﬁbroblast precursors
and enhances their differentiation towards ﬁbroblasts and theirmatura-
tion into myoﬁbroblasts in the infarcted heart. These ﬁndings were
accompanied by a reduced adverse remodeling in the AICAR-treated
group (evaluated by echocardiography) with signiﬁcantly improved
post-ischemic systolic and diastolic function (evaluated by Doppler).
2. Material and methods
2.1. Reagents
AICAR: 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
(Toronto Research Chemicals, Ontario, Canada).
2.2. Animals
14 month oldmale C57BL/6micewere purchased from the National
Institute of Aging and allowed oneweek to recover from shipping. Mice
were anesthetized, intubated, and underwent thoracotomy. A ligature
in a noose was placed around the LAD and the ends of the suture exte-
riorized to allow for closed chest induction ofmyocardial ischemia.Mice
were allowed to recover for one week. Mice were then reanesthetized
with 1% isoﬂurane and attached to an ECG board. The LADwas occluded
for 1 h with elevations of the ST segments monitored after which the
tension on the suture was released and reperfusion occurred. This
closed chest 1 h ischemia followed by reperfusion reproducibly pro-
duces a modest infarction in mice [19]. Mice were then followed from
5 days to 4 weeks. Mice were injected with AICAR intraperitoneally
(0.5 mg/g of body weight) every day for 7 days starting 2 days before
coronary occlusion. An equal volume of salinewas used to inject control
animals. Animals were used in agreement with the Baylor College of
Medicine Animal Care and Research Advisory Committee guidelines.
2.3. Cell isolation
5 days after MI, the hearts were excised, cut into 1 mm3 pieces and
digestedwith Liberase TH (RocheDiagnostics, Indianapolis, IN, USA), in-
cubated in a 37 °C shaking water bath with regular trituration by pipet
to obtain a single cell suspension. Afterwards, cells were centrifuged at
250 ×g for 5 min. The cell pellet was washed and then suspended in
PBS [4]. The isolated cell population contains only non-myocytes.
2.4. Flow cytometry
Cells were incubated with antibodies to CD45-PE (553081, BD
Pharmingen, San Diego, CA, USA) and CD44-biotin (731958, Beckman
Coulter, Brea, CA, USA) or the appropriate isotype controls followed
by streptavidin-PE–Cy5 (Beckman Coulter) and external antigens
were analyzed. For internal antigens samples were ﬁxed in 2%
paraformaldehyde with 0.1% saponin, washed and then incubated
with antibodies to collagen type I (600-401-103-05, Rockland Immuno-
chemicals, Gilbertsville, PA), α-SMA-FITC (F3777, Sigma, St. Louis, MO,
USA) or an IgG control. Then the secondary antibody conjugated toDyLight-488 (Jackson ImmunoResearch, West Grove, PA, USA) was ap-
plied and cells were analyzed on a Cell Lab Quanta SC ﬂow cytometer
(Beckman Coulter) using the Quanta Analysis software or FlowJo
(v.7.2.5, Tree Star Inc., Ashland, OR, USA). 50 nM calcein (Invitrogen,
Carlsbad, CA, USA) was added to non-ﬁxed samples to determine cell
viability. n = 4, 5 for saline and AICAR treated animals respectively.2.5. Whole heart lysate
The hearts were snap frozen in liquid nitrogen then ground under
liquid nitrogen to a ﬁne powder. The tissue powder was resuspended
in RIPA lysis buffer (Thermo Scientiﬁc, Rockford, IL, USA) supplemented
with protease and phosphatase inhibitor cocktail (Thermo Scientiﬁc).
Lysates were then frozen, thawed and centrifuged at 10,000 ×g for
5 min. Supernatant was aliquoted and stored at −80 °C until further
analysis.2.6. Western blot analysis
50 μg of protein was mixed with reducing Laemmli sample buffer
and separated on 4%–15% Tris–HCl gels (Bio-Rad, Hercules, CA, USA).
Proteins were then transferred to nitrocellulose membranes (Bio-Rad).
The membranes were incubated with antibodies diluted according to
the manufacturer's protocol. SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientiﬁc) was used to detect signals. Antibodies:
anti-pAMPK (2535, Cell Signaling, Danvers, MA, USA) and anti-AMPK
(2603, Cell Signaling). Densitometry analysis was performed using
ImageJ software (NIH, Bethesda, MD, USA). n = 4.2.7. Ultrasound procedure
2D echo guided M-mode images were acquired using a Vevo 770
RMV-707B 30-MHz probe (VisualSonics, Toronto, Canada). For the mi-
tral inﬂow and aortic outﬂow Doppler measurements a Doppler signal
processing workstation (DSPW, Indus Instruments, Houston, TX) was
employed using a 10-MHz (1 mm diameter) pulsed Doppler probe as
previously described [20]. Measurements of left ventricle function and
structure were performed prior to any surgery (pre) and then 1, 2, and
4 weeks after MI procedures. The following parameters were reported
as indicators of function and remodeling: left ventricular internal diam-
eter (diastole) LVID,d, ΔLVID,d = LVID,d(4 week) − LVID,d(1 week), E
peak velocity, isovolumic contraction time (IVCT), isovolumic relaxation
time (IVRT), peak aortic ﬂow velocity (PAFV), mean aortic acceleration,
left atrium (LA) dimensions and Tei index = (IVCT + IVRT) / ejection
time, apical end diastolic and end systolic dimensions were performed
as described [21]. n = 9, 10 for saline andAICAR treated animals respec-
tively except for apical diastolic and systolic dimensions where n = 5
for both group.2.8. Immunoﬂuorescence staining
Tissue was ﬁxed in zinc-Tris ﬁxative (modiﬁed from Beckstead) [22],
parafﬁn embedded and sectioned at a 5 μm thickness. Sections were
deparafﬁnized, permeabilized in PBS containing 1% Triton X-100, blocked
in 1% BSA and incubatedwith following antibodies overnight: anti-CD44-
PE (731959, Beckman Coulter), anti-procollagen type I (sc-25973, Santa
Cruz Biotechnology, Dallas, TX, USA), anti-αSMA-FITC (F3777, Sigma),
anti-LOX (L4669, Sigma), anti-wheat germagglutinin (W849, Invitrogen).
Subsequently sectionswerewashed and a secondary reagentwas applied
if applicable such as anti-goat or anti-rabbit IgG DyLight-488 conjugated
(Jackson ImmunoResearch, West Grove, PA, USA) or anti-rabbit IgG
DyLight-549 conjugated (Jackson ImmunoResearch). n = 4, 5 for saline
and AICAR treated animals respectively.
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IHC was performed on 5 μm parafﬁn heart sections using IHC kit
(Vector Laboratories, Burlingame, CA, USA). Following antibodies were
used: anti-pAMPK (2535, Cell Signaling), p-p38MAPK (4511, Cell Sig-
naling) and WT-1 (sc-192, Santa Cruz Biotechnology). Nuclei were
counterstainedwith hematoxylin. n = 4, 5 for saline and AICAR treated
animals respectively.
2.10. Polarized light assessment of ﬁbrillar collagen
The hearts were perfused ﬁrst with cardioplegic solution and there-
after with a zinc buffer [22] for 4 h before dehydration through alcohols
to xylene followed by embedding in parafﬁn. Sections were cut at 5 μm,
rehydrated and stained with picrosirius red (Sigma) [23] with a 0.01 N
HCl wash [24]. They were then dehydrated and mounted in Cytoseal-
XYL (Richard-Allan Scientiﬁc, Kalamazoo, MI, USA). The sections were
examined under brightﬁeld illumination with an Olympus CKX41 or
under an Olympus AX70microscope equipped with ﬁlters for linear po-
larization [24]. The polarizer was rotated to achieve extinction with the
analyzer, showing a black background and the birefringency of the
picrosirius red-stained collagen. Images were obtained with 10× and
40× objective lenses, recorded with an Olympus Q-color 3 digital cam-
era, and analyzed using ImageJ software. The RGB images were interro-
gated using the color threshold function for their hue spectrum (color
histograms). We then converted the RGB image to an HSB (hue, satura-
tion, brightness) stack and obtained histograms of the hue spectrum
that were quantiﬁed for each hue after setting the spectral limits for
red, orange, yellow, and green. n = 4, 5 for saline andAICAR treated an-
imals respectively.
2.11. Infarct size
Animals underwent 1 hour ischemia as described above. Twenty four
hours later 1% Evans bluewas perfused into the aorta and coronary arter-
ies, and then animals were sacriﬁced. The hearts were sectioned into
1 mm sections and then incubated in 1.5% triphenyltetrazolium chlo-
ride (Sigma) for 30 min. Sections were placed in formalin and photo-
graphs were taken 24 h later. Viable myocardium was red, the infarct
site appears pale white and area at risk (AAR) was blue [25]. The area
of infarction for each slice was determined by image analysis (ImageJ).
Infarct size was determined by applying the following formulas: infarct
weight = (A1 × Wt1) + (A2 × Wt2) + (A3 × Wt3) + (A4 × Wt4),
where A is a percent area of infarction by planimetry andWt is a weight
of each section. Percentage of infarcted LV = (infarct weight / LV
weight) × 100. AAR was determined using planimetry (ImageJ). n = 4
for infarct size studies and n = 3 for AAR evaluation.
2.12. Statistical analysis
Results are presented as mean ± SE. For statistical analysis an un-
paired Student's t-test with Welch's correction or one-way ANOVA
with Tukey's post-test was applied. Differences were considered statis-
tically signiﬁcant if p b 0.05.
3. Results
3.1. In vivo AICAR treatment activates AMPK in cells populating the
infarcted area
Micewere injected dailywith AICAR or saline for 7 days. Becausewe
hypothesized that AICAR treatment would mobilize endogenous pro-
genitors, AICAR injections started 2 days before occlusion. 5 days after
the MI, the hearts were excised and analyzed. Activation of AMPK was
assessed by the level of Thr172phosphorylation. Thr172 is locatedwith-
in the activation loop of the AMPK catalytic subunitα [26]. AMPK in thewhole heart lysate was activated in response to AICAR treatment, as we
found a 2 fold increase in AMPK phosphorylation in the AICAR-treated
group but the difference was not statistically signiﬁcant (p = 0.16)
(Fig. 1A). However, immunohistochemical analysis of non-myocyte
cells populating the infarcted area revealed a statistically signiﬁcant in-
crease of phosphorylated AMPK in the AICAR-treated group compared
to saline-treated mice (Fig. 1B). In other cell type (cardiomyocytes)
AICAR treatment has been shown to increase AMPK phosphorylation
for up to 24 h in [27] and in our experiment the hearts were excised
24 h after the last AICAR or saline injection.
3.2. AICAR mobilizes a pool of endogenous ﬁbroblast precursors
We recently reported that in the young infarcted heart 2 days after
injury the number of CD44posCD45neg mesenchymal precursors was el-
evated. The number of these cells peaks at 3 days post-MI and accounts
for ~5% of all viable non-myocyte cells [4]. To see if AMPK activation has
an effect on these cells, infarctedmicewere injected dailywith AICAR or
saline 2 days before occlusion and then throughout the reperfusion,
which lasted 5 days. Then, non-myocyte cells were isolated and ana-
lyzed by ﬂow cytometry. Our data indicated that AICAR treatment mo-
bilized CD44posCD45neg cells in the ischemic heart (Fig. 2A, left and
right panels). The number of CD44posCD45neg cells was doubled in
AICAR-stimulated hearts compared to saline-treated controls. The num-
ber of CD44posCD45negcollagenpos ﬁbroblasts (Fig. 2B) was increased in
the AICAR-treated heart by ~3 fold when compared to saline-treated
controls and the immunoﬂuorescence staining revealed an accumula-
tion of CD44posprocollagen type Ipos cells in the infarct of AICAR-
treated hearts as compared to controls (Fig. 2C). Note that almost all
cells in the infarcted area in the AICAR-treated heart are double positive.
The density of cells expressing procollagen in non-infarcted areas was
not affected by AICAR treatment (Fig. 2D).
Although the evidence suggests that ﬁbroblasts of hematopoietic
origin are not critical to repair after MI [28,29], AMPK may affect
transendothelial migration [30,31]. For this reason we evaluated the
number of cardiac CD45pos cells or their differentiation into ﬁbroblasts
and myoﬁbroblasts in AICAR treated animals. We found no signiﬁcant
difference (Supplemental Fig. 1), suggesting that endogenous precur-
sors but not blood-derived cells participate in AICAR-dependent en-
hanced repair after MI.
Recent studies have demonstrated that the epicardium can be acti-
vated after MI and that epicardial-derived cells can populate the dam-
aged area [32]. We analyzed the hearts excised 5 days post-occlusion
for the presence of Wilms' Tumor 1 antigen (WT1), an epicardial mark-
er. We found that only a small percentage of cells expressingWT1were
present in the epicardium, the subepicardium and the infarcted area;
however, the number of WT1pos cells within the infarcted area was in-
creased in AICAR-treated hearts (Supplemental Fig. 2). As TGF-β1 stim-
ulates epicardial-to-mesenchymal transition (EMT) [33] and AICAR
augments TGF-β1 signaling [9], the activated TGF-β1/AMPK pathway
may account for the elevated EMT in AICAR-treated hearts. Because of
the small portion of WT1pos cells in the infracted area they might be
contributing to a minor extent to ﬁbroblast formation in the aging
heart as suggested by others [32].
3.3. Improved scar formation in the AICAR-treated post-ischemic heart
The collagen content of the infarct scar was examined using
picrosirius red staining. Brightﬁeld images show the greater collagen
content in the scar of AICAR-treated animals compared to that of the sa-
line control (Fig. 3). Quantiﬁed collagen content in the scar area was
computed using ImageJ and plotted in a graph shown on the right
panel of Fig. 3.
To characterize the collagen structure further, we viewed the
picrosirius red stained sections under polarized light (see the Material
and methods section). This reveals the thickness of the collagen ﬁbrils,
Fig. 1. AICAR-dependent activation of AMPK. A. Phosphorylation of AMPK was doubled in the hearts isolated from AICAR-treated mice. Animals were treated with AICAR for 7 days. The
hearts were isolated 24 h after last AICAR injection. The middle panel shows densitometry results and the right panel shows Ponceau staining on the gel. n = 4. B. Non-myocytes popu-
lating the infarcted area express activated (phosphorylated) AMPK 5 days post-occlusion in AICAR-treated animals as evaluated by IHC staining. Cells were counterstainedwith hematox-
ylin. Scale bar = 50 μm. n = 4, 5 for saline and AICAR treated animals respectively. *Denotes p b 0.05. Student's t-test with Welch's correction was used for analysis.
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and the thickest ones red [34]. The images show not only the increased
collagen content in the scar (Figs. 4A, B), but also that the ﬁbrils are
thicker in the AICAR-treated animals than in the saline controls
(Fig. 4B). The shift in the spectrum of the collagen birefringency can
be seen in the color histograms (Fig. 4B) and this is quantiﬁed in the
graph (Fig. 4B, right panel). There are more small (green) ﬁbrils in the
saline control, andmore thick (red) ﬁbrils in the AICAR-treated animals,
indicating that AICAR-treated mice make a better scar.
To examine one possible reason for the increased collagen ﬁbril
thickness, we investigated the ability of cells in the infarct to cross-
link collagen by production of lysyl oxidase (LOX) [35]. It can be seen
in Fig. 4C that there are many more cells that are LOXpos in the AICAR-
treated scar. As expected, the number of LOX-expressing cells in non-
infarcted areas was much lower and was not signiﬁcantly different be-
tween saline and AICAR-treated hearts (Fig. 4D).
3.4. Increased myoﬁbroblast content in AICAR-treated post-ischemic heart
Scar density and mechanical effectiveness is also inﬂuenced by scar
contraction. We have previously shown that the in vitro rescue of defec-
tive aged ﬁbroblast maturation occurred via a non-canonical TGF-β/
AMPK pathway [9] that involves activation of p38MAPK. Our current
in vivo data support these ﬁndings. The number of CD44posα-SMApos
myoﬁbroblasts was increased in AICAR-treated hearts by 11 fold when
compared to the saline treated group (Fig. 5A) as evaluated by ﬂow cy-
tometry. Immunoﬂuorescence analysis of the infarct in the heart iso-
lated from animals treated with AICAR also indicated that the
damaged area was more densely populated with CD44posα-SMApos
myoﬁbroblasts (Fig. 5B) and with cells expressing phosphorylated/
activated p-p38MAPK (Fig. 5C) suggesting an enhanced myoﬁbroblast
maturation due to in vivo AMPK pathway activation.α-SMA expression
in cells residing in areas outside of the infarct was mostly associated
with blood vessels regardless of treatment (Fig. 5D).
3.5. Effect of in vivo AMPK activation on post-ischemic heart function
Next, we evaluated the role of AMPK activation in post-MI heart func-
tion. Again,micewere injectedwith AICAR or saline for 7 days (as above),
but followed for 4 weeks. Functional studies were performed before any
manipulation (pre) to establish the baseline and then after MI.
The left ventricle (LV) internal dimensions were not signiﬁcantly dif-
ferent between saline andAICAR at oneweek post-infarct (SupplementalTable 1A). Over the next three weeks, the saline treated mice increased
their left ventricular internal diameter in diastole (LVID,d) while the
AICAR treated had no change in dimension (Fig. 6A, Supplemental
Table 1A). We have reported previously that the aged heart displayed
adverse remodeling after MI [3]. These ﬁndings suggested that the
AICAR treatment prevented the post-infarction adverse remodeling in
older mice. Consistent with the effects on remodeling, AICAR preserved
diastolic and end systolic dimensions at the apical (site of infarct) post-
infarction (Fig. 6B) whereas diastolic dimension was signiﬁcantly in-
creased in saline treated group (end systolic dimension at the apex
appeared to be increased in saline treated animals aswell but the statis-
tical signiﬁcance was p = 0.16).
Doppler parameters were used to reﬂect global cardiac function. In
the older saline treated mice, there were decrements in the systolic
and diastolic function after 4 weeks post occlusion (Figs. 6C, D, and
Supplemental Table 1B). Peak Aortic Flow Velocity (PAFV) and mean
acceleration decreased (Fig. 6C, left and middle panels) about 10% at
four week post-infarct. For diastolic function Peak E decreased and
isovolumic relaxation time (IVRT) (Fig. 6D, left and right panels) was
prolonged at four week, consistent with worsened ﬁlling. By contrast,
the AICAR treated mice show preserved Peak E velocity, PAFV and Tei
index at 4 weeks post-infarct (Figs. 6C, D). To be certain the indices of
left ventricular ﬁlling in the AICAR-treatedmice did not result frompar-
adoxical increases in atrial ﬁlling pressure, we measured left atrial (LA)
dimensions in both control and AICAR-treated mice (Fig. 6D, middle
panel). There were no signiﬁcant changes seen in the left atrial dimen-
sions in either group over the time course of these experiments. Thus,
the differences seen are compatiblewith increased diastolic dysfunction
in the control group and preserved diastolic function of the AICAR-
treated group. Representative 2D M-Mode echo images from saline
and AICAR-treated mice are shown in Supplemental Fig. 3. The left
panel shows images acquired 1 weekpost-MI and the right panel repre-
sents images obtained 4 weeks post-MI. No dilation was observed in
AICAR-treated hearts.
It is important to emphasize that these experiments were donewith
the intention of evaluating the cell biology and pathophysiology of car-
diac repair in the aging animal and the potential remedial effects of
stimulating non-canonical TGF-β signaling. In previous experiments,
we have described that myocardial infarction in older animals has a
very highmortality rate [2]; therefore, we elected tomake small infarcts
to allow us sufﬁcient numbers of experimental survivors in each group
in a highly labile model. The infarct size in both groups was the same
modest in size (Supplemental Fig. 4B, discussed below) and, indeed,
Fig. 2. AICAR activates primitive endogenous precursors in the ischemic heart. Cells were isolated 5 days after occlusion. Daily AICAR or saline injections were given for 7 days, starting
2 days before occlusion. A. Cardiac CD44posCD45neg viable cell number is elevated byAICAR treatment. Right panel shows representative overlaid histograms. B. AMPK activation enhances
ﬁbroblast differentiation as the number of CD44posCD45negcollagen type Ipos cells was increased in the hearts isolated from AICAR-treated animals. C. Immunoﬂuorescence staining show-
ing increased accumulation of CD44posprocollagen type Ipos cells in the infarcted area of AICAR-treated mouse. Arrows indicate double stained cells. Scale bar = 50 μm. D. AICAR treat-
ment did not affect the number of procollagen type Ipos cells in non-infarcted areas. Scale bar = 200 μm. n = 4, 5 for saline and AICAR treated animals respectively. *Denotes
p b 0.05. Student's t-test with Welch's correction was used for analysis.
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plemental Table 1A) in the two groups at four weeks. Thus, both groups
were able to compensate for the injury despite their age. Nevertheless,Fig. 3. AICAR advances collagen deposition in the scar of the aged ischemic heart. Representativ
illustrates enhanced collagen deposition in the scar from AICAR-treated animals computed by
*Denotes p b 0.05. Student's t-test with Welch's correction was used for analysis.utilizing standard evaluators of systolic and diastolic function, AICAR
prevented the functional decrements seen in the saline treated mice at
four weeks, suggesting that, even in a compensated infarcted heart,e image of picrosirius red staining of collagen network 5 days after occlusion. Right panel
ImageJ. Scale bar = 200 μm. n = 4, 5 for saline and AICAR treated animals respectively.
Fig. 4.AICAR improves scar formation in the aged ischemic heart via enhanced collagen ﬁbril maturation. Representative images 5 days post-occlusion are shown. A. Lowermagniﬁcation
image showsmature collagenﬁbrils in AICAR-treatedmice. Scale bar = 200 μm. B. Highermagniﬁcation imageswere analyzed for the degree of collagen ﬁbermaturation. Green, yellow,
orange and red correspond to ﬁbrilmaturationwhere green corresponds to the thinnest and leastmature and red themostmature. Changes in colorwhere recorded in a histogram (inside
window) and used to calculate proportion of each ﬁber type in the scar of saline and AICAR-treatedmice (right panel graph). Scale bar = 50 μm. C. Representative images of LOX immu-
noﬂuorescence staining in the infarcted area (left panel). Right panel shows LOX expression evaluated as a number of positive cells per areawithin infarct. D. Representative images of LOX
immunoﬂuorescence staining in the non-infarcted area (left panel). Right panel shows LOX expression evaluated as a number of positive cells per area. Scale bar = 50 μm. n = 4, 5 for
saline and AICAR treated animals respectively. *Denotes p b 0.05. Student's t-test with Welch's correction was used for analysis.
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is possible that, over time, the regional dysfunction and the inherent de-
crease in ventricular efﬁciency from adverse remodelingmight result in
progression of heart failure even with a small infarct. It is to be noted
that, in aging patients, congestive heart failure frequently appears at
times remote from the initial infarction which apparent recovery has
occurred (reviewed in [36]).
To further evaluate adverse remodeling, heart sections (4 weeks
post-MI) were stained with picrosirius red (Fig. 7A). Because at this
time point analyzed sections contain not only collagen that forms scar
but also collagen contributing to interstitial ﬁbrosis in contrast to theresults presented in Fig. 3 showing exclusively scar-forming collagen,
we have chosen 3 sections per each heart separated by a 50–60 μmdis-
tance with the highest collagen content for analysis. We found that sa-
line treated mice had a 3.5 fold increase in collagen content when
compared to AICAR-treatedmice and that the difference was statistical-
ly signiﬁcant (Fig. 7A, right panel). Cardiomyocyte hypertrophy (as an-
other useful tool to analyze adverse remodeling) was evaluated by the
mean cross-sectional area of left ventricular cardiomyocytes in the in-
farct border zone and non-infarcted myocardium 4 weeks post-MI
(Fig. 7B). We observed that cardiomyocyte size in saline-treated hearts
when compared to AICAR-treated mice was increased by 15.5% in the
Fig. 5.AMPK activation promotesmyoﬁbroblast maturation in the aged heart. A. Increased number of CD44posCD45neg non-myocytes expressingα-SMA in the hearts from AICAR-treated
animals. B. Immunoﬂuorescence staining of CD44posα-SMApos cells in the infarcted area. Arrows indicate double stained cells. Scale bar = 50 μm. C. Representative images of phosphor-
ylated p38MAPK (p-p38MAPK) IHC staining in the infarcted area of saline and AICAR-treated hearts. Cells were counterstainedwith hematoxylin. Number of p-p38MAPKpos cells per total
number of cells populating infarcted area was plotted in a graph shown on a right panel. Scale bar = 50 μm. *Denotes p b 0.05. Student's t-test withWelch's correction was used for sta-
tistical analysis. D. Immunoﬂuorescence staining of α-SMApos cells in the non-infarcted area. Scale bar = 100 μm. n = 4, 5 for saline and AICAR treated animals respectively.
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cardiomyocyte hypertrophy as reported by others [37] however the ob-
served difference was not statistically signiﬁcant.
Heart weight to body weight ratios were not changed by AICAR
treatment as shown in Supplemental Fig. 4A and importantly, AICAR-
treatment did not affect the infarct size at 24 h of reperfusion (Supple-
mental Fig. 4B, left panel) nor was the area at risk compared to infarct
size statistically different in both groups (Supplemental Fig. 4B, right
panel). Total survival ratewas the same for both groups (95.1%). The an-
imals that died did so after implantation of a ligature before saline or
AICAR was injected (see the Material and methods section). 2/41 of
saline-treated and 2/41 of AICAR-treated animals died after occlusion.4. Discussion
Here we present new data showing that enhancement of AMPK
activation improves post-MI cardiac function in the aged heart via pro-
moting scar formation (see schema in Fig. 8). This effect was accom-
plished by counteracting the defective responses to TGF-β by cardiac
(myo)ﬁbroblast. Not only did the ﬁbroblasts deposit more collagen in
the scar (Fig. 3) which was comprised of more mature ﬁbrils (Figs. 4A,B), but they also expressed more α-SMA (Figs. 5A, B) with which they
contract the scar.
AMPK activity is stimulated via various pathways involving stress
(ischemic, oxidative, hypoglycemic), exercise, hormones (adiponectin,
leptin) and pharmacological agents (AICAR, metformin, A769662)
[38]. AMPK's role in post-ischemic heart protection is quite complex.
AMPK is activated due to an increased AMP:ATP ratio,which occurs dur-
ing an ischemic event. In cardiomyocytes, AMPK switches metabolism
to preserve energy [10] and reduces cardiac hypertrophy by targeting
protein synthesis [39]. It has been demonstrated that reduced AMPK ex-
pression in cardiomyocytes is damaging to the ischemic heart because
of the reduction of glucose uptake and ATP homeostasis, and increased
necrosis and apoptosis after injury [10]. AMPK cardioprotective proper-
ties are not only associated with cardiomyocytes since it has been dem-
onstrated that AMPK also promotes differentiation of endothelial
progenitor cells and vasculogenesis [18], decreases recruitment of
monocytes to endothelium and therefore lowers inﬂammation [31]
and as we demonstrated targets ﬁbroblast progenitors.
As the aging heart displays difﬁculties in healing afterMI, it has been
reported that the infarct size is actually reducedwith aging [2].We eval-
uated the infarct size of AICAR and saline-treated animals. We found
that infarct size in aged animals was relatively small (~12%) (as
Fig. 6.The effect of AMPKactivation on the agedmurine heart. Daily AICAR or saline injectionswere given for 7 days starting 2 days before occlusion. A. AICAR-dependent AMPKactivation
prevents adverse remodeling after MI. Parameters are the difference between 1 and 4 weeks afterMI in saline and AICAR treatedmice (left graph change inmm, right graph change in %).
n = 9, 10 for saline and AICAR treated animals respectively. B. Apical end diastolic (left panel) and end systolic (right panel) dimensions in AICAR and saline treatedmice. n = 5 for both
treatment groups. One-way ANOVAwith Tukey's post-test correction was used to evaluate statistical differences. C. Systolic and D. diastolic dysfunctions were prevented by AICAR treat-
ment. These data represent changes in the heart function at fourweeks post-MI compared to pre-values. For A, C and D Student's t-test was used for statistical analysis. *Denotes p b 0.05.
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or area at risk (Supplemental Fig. 4B). Despite the fact that ischemia it-
self markedly activates AMPK, it has been demonstrated in isolated
reperfused hearts that AICAR reduces infarct size in young animals
[40–42]. In this study the role of AICAR does not appear to relate to
myocardial infarction size; moreover, there is no apparent AICAR effect
seen in the ﬁrst week of infarction (AICAR treatment ceased 5 days
post-MI). Thus, the AICAR effect appears to relate to the facilitation
of an effective mechanical scar formation through action on non-
myocyte ﬁbroblast precursors.
The heart responds to injury by activating repairmechanisms [43]. In
one aspect of this repair, the number of MSC/ﬁbroblast precursors in-
creases andwithin a fewdays afterMI these cells differentiate intoﬁbro-
blasts and mature into myoﬁbroblasts [4]. We have shown in Figs. 1B,
2C, 4C, and 5B a signiﬁcant number of non-myocytes populating the in-
farcted area 5 days post-occlusion–reperfusion and indicated that these
cells differentiate into (myo)ﬁbroblasts. Post-occlusion CD44posCD45neg
inﬁltrates in the infarcted area has been reported by Carlson et al. [4]
that peak at day 3 post-MI and then differentiate into CD44posﬁbroblast
and CD44posmyoﬁbroblast by days 5 and 7 post-occlusion reperfusionrespectively [4]. Although it has been shown that neutrophils and mac-
rophages also inﬁltrate infarcted area, in the murine heart it is a robust
but transient event and by day 5 post-occlusion (the time frame we
mostly studied) the content of inﬂammatory cells most likely was re-
duced as indicated by the timecourse described by Dewald et al. [44].
We recently reported that aged cardiac MSC were characterized by
defective ﬁbroblast differentiation and function [9], linked to reduced
TβRI expression inMSC and consequent impairment of the TGF-β canon-
ical pathway and downstream induction of α-SMA in myoﬁbroblasts.
The MSC defect could be reduced by stimulation of a non-canonical
pathway [9] and led to the present study. In our in vivo study, AICAR
treatment resulted in doubling the number of ﬁbroblast precursors
(CD44posCD45neg) in the ischemic area (Fig. 2A). Differentiation of pre-
cursors into ﬁbroblasts andmyoﬁbroblasts in a setting of post-MI recov-
ery in the aged heart has been shown to be reduced compared to what
we observed in the young hearts [3]. At 5 days post-MI (peak for ﬁbro-
blast differentiation) the CD44posCD45neg ﬁbroblast and myoﬁbroblast
content in saline-treated mice was equal or lower to what we observed
in sham-operated young animals [4]. However AICAR treatment in-
creased the number of these cells to the level observed in young animals
Fig. 7. AICAR treatment reduces post-MI adverse remodeling. A. Representative images of picrosirius red staining of collagens in heart sections 4 weeks post-MI. Right panel illustrates
elevated collagen deposition per area as computed by ImageJ. Scale bar = 200 μm. *Denotes p b 0.05. Student's t-test with Welch's correction was used for analysis. B. Cardiomyocyte
hypertrophy was evaluated by wheat germ agglutinin staining. Cell area was computed by analyzing cross-sectioned area of the heart using ImageJ software. At least 100 cells per
heart section and 2 sections per mouse were analyzed. n = 4, 5 for saline and AICAR treated animals respectively. 3 sham animals were used per treatment group. *Denotes p b 0.05.
One-way ANOVA with Tukey's post-test correction was used to evaluate statistical differences.
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enhanced differentiation.
TGF-β signaling is crucial for scar contraction and collagen deposi-
tion [6,43,45–48]. In the agedmurine heart, we found that collagen con-
tent in the cardiac scar is markedly attenuated in aged mouse infarcts,
resulting in the formation of a scar that contains loose connective tissue
[3]. However, cells within the infarct site in the hearts treated with
AICARexpressedmore LOX, an enzyme essential for cross-linking of col-
lagens (Fig. 4C). It has been demonstrated that both LOX transcript level
and enzymatic activity and α-SMA expression are controlled by TGF-β
[6,49]. Thus AICAR activation of a non-canonical TGF-β/AMPK pathway
may promote transcriptional regulation of other TGF-β-sensitive genes.
As we have demonstrated in vivo increased phosphorylation of
p38MAPK in AICAR-treated hearts that were speciﬁcally targeted to
the infarcted area (Fig. 5C), we further conﬁrmed the importance ofFig. 8. A proposed overview of AMPK-dependent regulation of post-MI scar formation in
the aged heart. AICAR treatment in the aged heart activates AMPK. AMPKphosphorylation
increases TGF-β responsiveness via activation of a non-canonical TGF-β pathway. En-
hanced TGF-β signaling results in increased collagen and α-SMA expressions. Elevated
collagen deposition and scar contraction leads to the formation of a competent scar that
improves post-ischemic heart function and prevents adverse remodeling.AMPK→ p38MAPK→ SMA pathway that was previously character-
ized in vitro [9]. The functional association between AMPK and
p38MAPK activities has been characterized by others in cardiomyocytes
[50]. Furthermore in cardiomyocytes, the AMPK/p38MAPK axis de-
pends on TGF-β signaling similar to what we described previously
in vitro in myoﬁbroblasts [9].
AICAR's cardioprotective role (other than reported in this manu-
script), has been described by others. It has been demonstrated that
AICAR reduces migration and proliferation of vascular smooth muscle
cells following balloon injury [51], inhibits Na+/H+ exchanger during
reperfusion [52] andmay inhibit ceramide accumulation thus preventing
fatty acid induced apoptosis [53]. AICAR also reduces obesity related in-
ﬂammation, improves insulin sensitivity [54] and increases lipolysis
[55] that is also beneﬁcial for the heart. Although AICAR has targets
other than AMPK, the use of other activators also has been problematic
due to speciﬁcity issues [56,57]. We recognize that this study has limita-
tions and we intend to follow up with more detailed analyses using dif-
ferent AMPK activators and different times of application such as during
occlusion or reperfusion. However, AICAR preconditioning prior to ische-
mia (similar to what we reported) has been shown to be beneﬁcial and
prevented post-ischemic leukocyte adhesion [58]. The purpose of the
current study was to establish if AICAR mobilizes endogenous cardiac
CD44pos precursors and improves scar formation. Our data suggest that
AICAR targets CD44pos ﬁbroblasts precursors and enhances their differ-
entiation. It has been demonstrated that the CD44 transmembrane
protein is essential for ischemia-dependent AMPK activation [59],
suggesting that perhaps two signaling pathways (ischemia and activa-
tion by pharmacological agent) are necessary to achieve optimal level
of AMPK activity in the older heart especially that reduced AMPK activa-
tion was observed in the aged heart [60] and cardiac ﬁbroblasts [9].
In a recently reported large clinical trial, investigators found that
AICAR therapy resulted only in mild side effects such as increased uric
acid and hyperuricemia [61] however AICAR application did not reduce
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bypass graft surgery. Our data presented here indicate that different ap-
plications for AICAR therapy such as improvement of post-MI scar for-
mation may prove more beneﬁcial.
5. Conclusions
In summary, we present new evidence that short-term AICAR-
dependent AMPK activation in the aged ischemic heart improves scar for-
mation and thereby results in better systolic and diastolic function and
prevents adverse post-ischemic remodeling. We attribute the beneﬁcial
role of AICAR treatment to increased differentiation of MSC into ﬁbro-
blasts and their subsequent maturation into functional myoﬁbroblasts.
After further study, these ﬁndings may suggest a potential mechanism
by which AMPK activation in the aged ischemic heart may be developed
into a therapeutic strategy for older patients suffering fromMI.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2013.07.005.
Sources of funding
This work was supported by the Hufﬁngton Center on Aging grant
(KC), NIH grant R01HL089792 (MLE), the Medallion Foundation grant




We would like to thank Dorellyn B. Lee, Hao Zhang, Jennifer Pocius
and Thuy Pham for their excellent technical assistance.
References
[1] Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart dis-
ease and stroke statistics—2012 update: a report from the American Heart Associa-
tion. Circulation 2012;125:e2-220.
[2] Gould KE, Taffet GE, Michael LH, Christie RM, Konkol DL, Pocius JS, et al. Heart failure
and greater infarct expansion inmiddle-agedmice: a relevantmodel for postinfarction
failure. Am J Physiol Heart Circ Physiol 2002;282:H615–21.
[3] Bujak M, Kweon HJ, Chatila K, Li N, Taffet G, Frangogiannis NG. Aging-related defects
are associated with adverse cardiac remodeling in a mouse model of reperfused
myocardial infarction. J Am Coll Cardiol 2008;51:1384–92.
[4] Carlson S, Trial J, Soeller C, Entman ML. Cardiac mesenchymal stem cells contribute
to scar formation after myocardial infarction. Cardiovasc Res 2011;91:99–107.
[5] Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. Stimulation of type I
collagen transcription in human skin ﬁbroblasts by TGF-beta: involvement of Smad
3. J Invest Dermatol 1999;112:49–57.
[6] Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1
induces alpha-smooth muscle actin expression in granulation tissue myoﬁbroblasts
and in quiescent and growing cultured ﬁbroblasts. J Cell Biol 1993;122:103–11.
[7] Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium:
simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res
1999;44:232–41.
[8] Crawford JR, Haudek SB, Cieslik KA, Trial J, EntmanML. Origin of developmental pre-
cursors dictates the pathophysiologic role of cardiac ﬁbroblasts. J Cardiovasc Transl
Res 2012;5:749–59.
[9] Cieslik KA, Trial J, Entman ML. Defective myoﬁbroblast formation from mesenchy-
mal stem cells in the aging murine heart rescue by activation of the AMPK pathway.
Am J Pathol 2011;179:1792–806.
[10] Russell III RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated
protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac
dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495–503.
[11] Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, et al. Characteriza-
tion of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting
acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys
Acta 1996;1301:67–75.
[12] Carvajal K, Zarrinpashneh E, Szarszoi O, Joubert F, Athea Y, Mateo P, et al. Dual car-
diac contractile effects of the alpha2-AMPK deletion in low-ﬂow ischemia and reper-
fusion. Am J Physiol Heart Circ Physiol 2007;292:H3136–47.
[13] Zarrinpashneh E, Carjaval K, Beauloye C, Ginion A, Mateo P, Pouleur AC, et al. Role of
the alpha2-isoform of AMP-activated protein kinase in themetabolic response of the
heart to no-ﬂow ischemia. Am J Physiol Heart Circ Physiol 2006;291:H2875–83.[14] Russell III RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial
GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J
Physiol 1999;277:H643–9.
[15] Dzeja PP, Chung S, Faustino RS, Behfar A, Terzic A. Developmental enhancement of
adenylate kinase-AMPKmetabolic signaling axis supports stem cell cardiac differen-
tiation. PLoS One 2011;6:e19300.
[16] Padmasekar M, Sharifpanah F, Finkensieper A, Wartenberg M, Sauer H. Stimula-
tion of cardiomyogenesis of embryonic stem cells by nitric oxide downstream of
AMP-activated protein kinase and mTOR signaling pathways. Stem Cells Dev
2011;20:2163–75.
[17] Kim EK, Lim S, Park JM, Seo JK, Kim JH, Kim KT, et al. Humanmesenchymal stem cell
differentiation to the osteogenic or adipogenic lineage is regulated by AMP-activated
protein kinase. J Cell Physiol 2012;227:1680–7.
[18] Li X, Han Y, Pang W, Li C, Xie X, Shyy JY, et al. AMP-activated protein kinase pro-
motes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc
Biol 2008;28:1789–95.
[19] Nossuli TO, Lakshminarayanan V, Baumgarten G, Taffet GE, Ballantyne CM, Michael
LH, et al. A chronic mouse model of myocardial ischemia–reperfusion: essential in
cytokine studies. Am J Physiol Heart Circ Physiol 2000;278:H1049–55.
[20] Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, EntmanML. Immune-inﬂammatory
dysregulation modulates the incidence of progressive ﬁbrosis and diastolic stiffness in
the aging heart. J Mol Cell Cardiol 2011;50:248–56.
[21] Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters Jr WL, et al. A
new, simpliﬁed and accurate method for determining ejection fraction with
two-dimensional echocardiography. Circulation 1981;64:744–53.
[22] Beckstead JH. A simple technique for preservation of ﬁxation-sensitive antigens in
parafﬁn-embedded tissues. J Histochem Cytochem 1994;42:1127–34.
[23] Constantine VS, Mowry RW. Selective staining of human dermal collagen. II. The use of
picrosirius red F3BA with polarization microscopy. J Invest Dermatol 1968;50:419–23.
[24] Junqueira LC, Cossermelli W, Brentani R. Differential staining of collagens type I, II
and III by sirius red and polarization microscopy. Arch Histol Jpn 1978;41:267–74.
[25] Briaud SA, Ding ZM, Michael LH, Entman ML, Daniel S, Ballantyne CM. Leukocyte
trafﬁcking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice.
Am J Physiol Heart Circ Physiol 2001;280:H60–7.
[26] Hawley SA, DavisonM,Woods A, Davies SP, Beri RK, Carling D, et al. Characterization
of the AMP-activated protein kinase kinase from rat liver and identiﬁcation of
threonine 172 as the major site at which it phosphorylates AMP-activated protein
kinase. J Biol Chem 1996;271:27879–87.
[27] Baskin KK, Taegtmeyer H. AMP-activated protein kinase regulates E3 ligases in ro-
dent heart. Circ Res 2011;109:1153–61.
[28] Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, et al.
CCL2/monocyte chemoattractant protein-1 regulates inﬂammatory responses criti-
cal to healing myocardial infarcts. Circ Res 2005;96:881–9.
[29] Yano T, Miura T, Ikeda Y, Matsuda E, Saito K, Miki T, et al. Intracardiac ﬁbroblasts, but
not bonemarrow derived cells, are the origin of myoﬁbroblasts inmyocardial infarct
repair. Cardiovasc Pathol 2005;14:241–6.
[30] Martinelli R, Gegg M, Longbottom R, Adamson P, Turowski P, Greenwood J.
ICAM-1-mediated endothelial nitric oxide synthase activation via calcium and
AMP-activated protein kinase is required for transendothelial lymphocyte migra-
tion. Mol Biol Cell 2009;20:995–1005.
[31] Zhang Y, Qiu J, Wang X, Xia M. AMP-activated protein kinase suppresses endothelial
cell inﬂammation through phosphorylation of transcriptional coactivator p300.
Arterioscler Thromb Vasc Biol 2011;31:2897–908.
[32] van Wijk B, Gunst QD, Moorman AF, van den Hoff MJ. Cardiac regeneration from ac-
tivated epicardium. PLoS One 2012;7:e44692.
[33] Sridurongrit S, Larsson J, Schwartz R, Ruiz-Lozano P, Kaartinen V. Signaling via the
Tgf-beta type I receptor Alk5 in heart development. Dev Biol 2008;322:208–18.
[34] Rich L, Whitteker P. Collagen and picrosirius red staining: a polarized light assess-
ment of ﬁbrillar hue and spatial distribution. Braz J Morphol Sci 2005;22:97–104.
[35] MacKenna DA, Omens JH, McCulloch AD, Covell JW. Contribution of collagen matrix
to passive left ventricular mechanics in isolated rat hearts. Am J Physiol 1994;266:
H1007–18.
[36] Jelani A, Jugdutt BI. STEMI and heart failure in the elderly: role of adverse remodel-
ing. Heart Fail Rev 2010;15:513–21.
[37] Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying
genotype-dependent efﬁcacy of single and combined PI3K- and MAPK-pathway in-
hibition in cancer. Proc Natl Acad Sci U S A 2009;106:18351–6.
[38] Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions
in the heart. Circ Res 2012;111:800–14.
[39] Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated pro-
tein kinase inhibits protein synthesis associated with hypertrophy in the cardiac
myocyte. J Biol Chem 2004;279:32771–9.
[40] Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM.
Transitory activation of AMPK at reperfusion protects the ischaemic–reperfused
rat myocardium against infarction. Cardiovasc Drugs Ther 2010;24:25–32.
[41] Kingma Jr JG, Simard D, Rouleau JR. Timely administration of AICA riboside reduces
reperfusion injury in rabbits. Cardiovasc Res 1994;28:1003–7.
[42] Kristiansen SB, Solskov L, Jessen N, Lofgren B, Schmitz O, Nielsen-Kudsk JE, et al.
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases myocardial
glucose uptake during reperfusion and induces late pre-conditioning: potential
role of AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2009;105:10–6.
[43] Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction
and cardiac remodeling. Cardiovasc Res 2007;74:184–95.
[44] Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, et al. Of mice and dogs:
species-speciﬁc differences in the inﬂammatory response following myocardial in-
farction. Am J Pathol 2004;164:665–77.
36 K.A. Cieslik et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 26–36[45] Gabbiani G. The myoﬁbroblast in wound healing and ﬁbrocontractive diseases. J
Pathol 2003;200:500–3.
[46] Serini G, Gabbiani G. Mechanisms of myoﬁbroblast activity and phenotypic modula-
tion. Exp Cell Res 1999;250:273–83.
[47] Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle
actin expression upregulates ﬁbroblast contractile activity. Mol Biol Cell
2001;12:2730–41.
[48] Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-induced
alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol 2003;29:
397–404.
[49] Shanley CJ, Gharaee-Kermani M, Sarkar R, Welling TH, Kriegel A, Ford JW, et al.
Transforming growth factor-beta 1 increases lysyl oxidase enzyme activity and
mRNA in rat aortic smooth muscle cells. J Vasc Surg 1997;25:446–52.
[50] Li J, Miller EJ, Ninomiya-Tsuji J, Russell III RR, Young LH. AMP-activated protein ki-
nase activates p38 mitogen-activated protein kinase by increasing recruitment of
p38 MAPK to TAB1 in the ischemic heart. Circ Res 2005;97:872–9.
[51] Stone JD, Narine A, Shaver PR, Fox JC, Vuncannon JR, Tulis DA. AMP-activated
protein kinase inhibits vascular smooth muscle cell proliferation and migration
and vascular remodeling following injury. Am J Physiol Heart Circ Physiol
2013;304:H369–81.
[52] Moopanar TR, Xiao XH, Jiang L, Chen ZP, Kemp BE, Allen DG. AICAR inhibits the
Na+/H+ exchanger in rat hearts–possible contribution to cardioprotection. Pﬂugers
Arch 2006;453:147–56.
[53] Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, et al. AMPK inhibitor Com-
pound C stimulates ceramide production and promotes Bax redistribution and apo-
ptosis in MCF7 breast carcinoma cells. J Lipid Res 2009;50:2389–97.
[54] Yang Z, Wang X, He Y, Qi L, Yu L, Xue B, et al. The full capacity of AICAR to reduce
obesity-induced inﬂammation and insulin resistance requires myeloid SIRT1. PLoS
One 2012;7:e49935.
[55] Gaidhu MP, Fediuc S, Anthony NM, So M, Mirpourian M, Perry RL, et al. Prolonged
AICAR-induced AMP-kinase activation promotes energy dissipation in white adipo-
cytes: novel mechanisms integrating HSL and ATGL. J Lipid Res 2009;50:704–15.
[56] Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF. A-769662 activates AMPK
beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am J Physiol Cell Physiol 2009;297:
C1041–52.
[57] Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition
of AMP deaminase. J Biol Chem 2011;286:1–11.
[58] Gaskin FS, Kamada K, Yusof M, Korthuis RJ. 5′-AMP-activated protein kinase ac-
tivation prevents postischemic leukocyte–endothelial cell adhesive interactions.
Am J Physiol Heart Circ Physiol 2007;292:H326–32.
[59] Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage migration
inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart.
Nature 2008;451:578–82.
[60] Ma H, Wang J, Thomas DP, Tong C, Leng L, WangW, et al. Impaired macrophage mi-
gration inhibitory factor-AMP-activated protein kinase activation and ischemic re-
covery in the senescent heart. Circulation 2010;122:282–92.
[61] Newman MF, Ferguson TB, White JA, Ambrosio G, Koglin J, Nussmeier NA, et al. Ef-
fect of adenosine-regulating agent acadesine on morbidity and mortality associated




TGF-β: transforming growth factor-β
α-SMA: α-smooth muscle actin
AMPK: AMP activated protein kinase
p38MAPK: p38 mitogen-activated protein kinase
LVID: left ventricular internal diameter
LVPW: left ventricular posterior wall thickness
RWT: relative wall thickness
IVCT: isovolumic contraction time
IVRT: isovolumic relaxation time
PAFV: peak aortic ﬂow velocity
LAD: left anterior descending coronary artery
LOX: lysyl oxidase
